Walmart Health enters into its first care coordination agreements

Walmart announced it has entered into agreements with a healthcare payer and a network of hospitals, with the stated aim of improving patient care coordination.

According to an announcement from Walmart Health—the retailer’s healthcare division—the agreements with insurer Ambetter Health and the Orlando Health community hospital network would allow central Florida residents in seven counties to obtain coordinated care and seek referrals for services as long as they’re covered by the Ambetter Value Plan.

Walmart Health offers primary care services both in-person and virtually, including dental and behavioral health plus labs, X-rays, EKGs and more. However, its limited specialty practice model leaves gaps that this agreement with Orlando Health is designed to fill. 

“By collaborating with Walmart Health and focusing on care coordination in the shared patient populations, we’ll be better positioned to more quickly identify patient needs and improve outcomes together in the Orlando area,” Cary D’Ortona, senior vice president at Orlando Health, said in a statement

The deal marks the first agreement Walmart has made with a health system to facilitate coordinated patient care, the statement says. Last year Walmart Health did enter into a value-based reimbursement agreement with UnitedHealthcare, which also provided Walmart Heath centers in Florida and Georgia with data analytics support aimed at cost containment and improving patient outcomes. 

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.